Literature DB >> 15053919

Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase.

Arusha Oloumi1, Timothy McPhee, Shoukat Dedhar.   

Abstract

Integrin-linked kinase (ILK) is a serine/threonine protein kinase which interacts with the cytoplasmic domains of beta1 and beta3 integrins. ILK structure and its localization at the focal adhesion allows it not only to interact with different structural proteins, but also to mediate many different signalling pathways. Extracellular matrices (ECM) and growth factors each stimulate ILK signalling. Constitutive activation of ILK in epithelial cells results in oncogenic phenotypes such as disruption of cell extracellular matrix and cell to cell interactions, suppression of suspension-induced apoptosis, and induction of anchorage independent cell growth and cell cycle progression. More specifically, pathological overexpression of ILK results in down-regulation of E-cadherin expression, and nuclear accumulation of beta-catenin, leading to the subsequent activation of the beta-catenin/Tcf transcription complex, the downstream components of the Wnt signalling pathway. Here we review the data implicating ILK in the regulation of these two signalling pathways, and discuss recent novel insights into the molecular basis and requirement of ILK in the process of epithelial to mesenchymal transformation (EMT).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053919     DOI: 10.1016/j.bbamcr.2003.12.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  53 in total

1.  The Role of Integrin Expressing Cells in Modulating Disease Susceptibility and Progression (January 2016).

Authors:  Aftab A Ansari; Siddappa N Byrareddy
Journal:  Int Trends Immun       Date:  2016-01

Review 2.  Crossroads of integrins and cadherins in epithelia and stroma remodeling.

Authors:  Carolina Epifano; Mirna Perez-Moreno
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

Review 3.  Wounds that will not heal: pervasive cellular reprogramming in cancer.

Authors:  Jung S Byun; Kevin Gardner
Journal:  Am J Pathol       Date:  2013-02-22       Impact factor: 4.307

4.  Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin.

Authors:  András Masszi; Lingzhi Fan; László Rosivall; Christopher A McCulloch; Ori D Rotstein; István Mucsi; András Kapus
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

5.  Overexpression of integrin-linked kinase (ILK) promotes glioma cell invasion and migration and down-regulates E-cadherin via the NF-κB pathway.

Authors:  Feng Liang; Shuqin Zhang; Bing Wang; Jianwu Qiu; Yunjie Wang
Journal:  J Mol Histol       Date:  2013-09-13       Impact factor: 2.611

6.  Integrin-linked kinase cytoplasmic and nuclear expression in laryngeal carcinomas.

Authors:  Anastasios K Goulioumis; Vasiliki Bravou; John Varakis; Panos Goumas; Helen Papadaki
Journal:  Virchows Arch       Date:  2008-09-24       Impact factor: 4.064

7.  SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling.

Authors:  Jing Nie; E Helene Sage
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

8.  Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development.

Authors:  Arusha Oloumi; Mykola Maidan; Frances E Lock; Howard Tearle; Steven McKinney; William J Muller; Samuel A J R Aparicio; Shoukat Dedhar
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466

9.  SPARC functions as an inhibitor of adipogenesis.

Authors:  Jing Nie; E Helene Sage
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2.

Authors:  Steve P Crampton; Beibei Wu; Edward J Park; Jai-Hyun Kim; Candice Solomon; Marian L Waterman; Christopher C W Hughes
Journal:  PLoS One       Date:  2009-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.